Preclinical and clinical effects of erythropoietin in the management of anaemia in patients with non-small cell lung cancer

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1745-1757

  Dempke, Wolfram ^a,b  

^a TTG Bochum   (Germany)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Chemotherapy; Efficacy; Erythropoietin; NSCLC; Radiotherapy; Response rates; Review

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOKINE; CYTOSTATIC AGENT; DOCETAXEL; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GEMCITABINE; HEMOGLOBIN; IRON; NAVELBINE; PACLITAXEL;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; ERYTHROPOIESIS; EVIDENCE BASED MEDICINE; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPOXIA; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; META ANALYSIS; MOLECULAR BIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; STEADY STATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

ANEMIA; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; ERYTHROPOIETIN; HUMANS; LUNG NEOPLASMS;

EID: 34250774379     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (86)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 49: 8-31, 1999.
2. Numico G, Russi E and Merlano M: Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy? Lung Cancer 32: 213-226, 2001.
3. Tester W and Mora J: Innovative treatments for advanced non-small cell lung cancer. Expert Opin Investig Drugs 10: 1021-1032, 2001.
4. Thatcher N, Ranson M, Lee SM, Niven N and Anderson H: Chemotherapy in non-small cell lung cancer. Ann Oncol 6(Suppl 1): 83-93, 1995.
5. Shepherd FA: Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol 26(Suppl 4): 3-11, 1999.
6. Cardenal F, Paz Lopez-Cabrerizo M, Anton A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, Garcia M, Lianes P, Montalar J, Vadell C, Gonzalez-Larriba JL, Nguyen B, Artal A and Rosell R: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17: 12-18, 1999.
7. Bonomi P, Kim KM, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M and Johnson D: Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631, 2000.
8. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Olak J, Stover D, Strawn JR, Turrisi AT and Somerfield MR: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 21: 330-353, 2003.
9. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. New Engl J Med 346: 92-98, 2002.
10. Finkelstein DM, Ettinger DS and Ruckdeschel JC: Long-term survivors in metastatic on-small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 4: 702-709, 1986.
11. Ohlhauser C, Bülzebruck H, Ebert W, Drings P and Wannenmacher M: Prognostic factors for survival in inoperable non-small cell lung cancer: a multivariate regression analysis of 456 patients with radiation therapy. Onkologie 20: 126-131, 1997.
12. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E and Rapoport B: Effects of epoietin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-2874, 2001.
13. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB and Musil J: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Inst Cancer 94: 1211-1220, 2002.
14. Cheung JY and Miller BA: Molecular mechanisms of erythropoietin signaling. Nephron 87: 215-222, 2001.
15. Remy I, Wilson IA and Michnick SW: Erythropoietin receptor activation by a ligand-induced conformation change. Science 283: 990-993, 1999.
16. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK and Wilson IA: Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand binding activation. Science 283: 987-990, 1999.
17. L through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 274: 22165-22169, 1999.
18. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G and Ihle JN: Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395, 1998.
19. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C and Lodish HF: Ineffective erythropoiesis in Stat5a (-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 98: 3261-3273, 2001.
20. L allows factor-independent differentiation of primary erythroblasts. Curr Biol 12: 1076-1085, 2002.
21. Weiss MJ: New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. Oncologist 8(Suppl 3): 18-29, 2003.
22. Dempke W, von Poblozki A, Grothey A and Schmoll HJ: Human hematopoietic growth factors: old lessons and new perspectives. Anticancer Res 20: 5155-5164, 2000.
23. Jelkmann W: Erythropoietin: structure, control of production and function. Physiol Rev 72: 449-489, 1992.
24. Weiss G and Goodnough LT: Anemia of chronic disease. New Engl J Med 352: 1011-1023, 2005.
25. Knight K, Wade S and Balduci L: Prevalence and outcome of anaemia in cancer: a systematic review of the literature. Am J Med 116(Suppl 7A): 11-26, 2004.
26. Honda K, Ishiko O, Tatsuta I, Deguchi M, Hirai K, Nakata S, Sumi T, Yasui T and Ogita S: Anemia-inducing substances from plasma of patients with advanced malignant neoplasms. Cancer Res 55: 3623-3628, 1995.
27. Byrd TF and Horwitz MA: Regulation of transferrin receptor expression and ferritin content in human mononuclear phagocytes: coordinate upregulation by iron transferrin and downregulation by interferon-gamma. J Clin Invest 91: 969-976, 1993.
28. Auerbach M, Ballard H, Trout R, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L and Rana J: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22: 1301-1307, 2005.
29. Means RT and Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80: 1639-1647, 1992.
30. Graziadei I, Gaggl S, Kaserbacher R, Braunsteiner H and Vogel W: The acute-phase protein α1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake. Blood 83: 260-268, 1994.
31. Ulich TR, Shin SS and del Castillo J: Haematologic effects of TNF. Res Immunol 144: 347-354, 1993.
32. Means RT: Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 13: 32-37, 1995.
33. Jelkmann W, Pagel H, Wolff M and Fandrey J: Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 50: 301-308, 1991.
34. Wolff M and Jelkmann W: Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human heptoma cultures. Ann Hematol 66: 27-31, 1993.
35. Birgegard G, Apro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll HJ, Schneider M, Schrijvers D, Shasha D and van Belle S: Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 68(Suppl 1): 3-11, 2005.
36. Vaupel P, Thews O and Hoeckel M: Treatment resistance of solid tumors. Role of hypoxia and anemia. Med Oncol 18: 243-259, 2001.
37. Evans JC and Bergsjö P: The influence of anemia on the results of radiotherapy in carcinoma of the cervix. Radiology 84: 709-717, 1965.
38. Lappin TR, Maxwell AP and Johnston PG: EPO's alter ego: erythropoietin has multiple actions. Stem Cells 20: 485-492, 2002.
39. Henry DH: The evolving role of epoetin alfa in cancer therapy. Oncologist 9: 97-107, 2004.
40. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S and Kuck KH: Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64: 326-333, 2002.
41. Arcasoy MO, Amin K and Haroon ZA: Erythropoietin (EPO) receptor expression in macrophages is associated with EPO-mediated stimulation of wound healing response, angiogenesis and transforming growth factor β-1 production. Proc Am Soc Hematol 100: 681a, 2002.
42. Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L, Devic S and Chow TY: Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 12: 1525-1532, 2004.
43. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET and Petit E: A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19: 643-651, 1999.
44. Grogan M, Thomas GM, Melamed I, Wong FLW, Pearcey RG, Joseph PK, Portelance L, Crook J and Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528-1536, 1999.
45. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E and Lavey RS: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Rad Oncol Biol Phys 50: 705-715, 2001.
46. Pradier O, Lederle K, Hille A, Weiss E, Christiansen H, Schmidberger H and Hess CF: Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: phase II trial with special reference to the hemoglobin level a prognostic parameter. J Cancer Res Clin Oncol 131: 261-269, 2005.
47. Henry DH: Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update. Expert Opin Pharmacother 6: 295-310, 2005.
48. Ludwig H, Birgegard G and Barrett-Lee P: Prevalence and management of anemia in patients (pts) with hematologic malignancies (HMs) and solid tumors (STs): results from the European Cancer Anaemia Survey (ECAS). Blood 100: 234a-235a, 2002.
49. Del Mastro L, Gennari A and Donati S: Chemotherapy of non-small cell lung cancer: role of erythropoietin in the management of anemia. Ann Oncol 10(Suppl 5): 91-94, 1999.
50. De Campos E, Radford J and Steward W: Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small cell lung cancer. J Clin Oncol 13: 1623-1631, 1995.
51. Miller CB, Platanias LC and Mills SR: Phase I-III trial of erythropoietin in the treatment of cisplatin-associated anaemia. J Natl Cancer Inst 84: 98-103, 1992.
52. Skillings JR, Sridhar FG, Wong C and Paddock L: The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 16: 22-25, 1993.
53. Ludwig H, Sundal E and Pecherstorfer M: Recombinant human erythropoietin for the correction of cancer associated anemia with or without concomitant cytotoxic chemotherapy. Cancer 76: 2319-2329, 1995.
54. Kunikane H, Watanabe K, Fukuoka M, Saijo N, Furuse K, Iklegami H, Ariyoshi Y and Kishimoto S: Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 6: 296-301, 2001.
55. Casas F, Vinolas N, Ferrer F, Farrus B, Gimferrer JM, Agusti C, Belda J and Luburich P: Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 55: 116-124, 2003.
56. Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, Janinis D, Pectasides D, Pavlidis N and Fountzilas G: Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 64: 102-110, 2003.
57. Boogaerts M, Oberhoff C, Ten Bokkel Huinink W, Nowrousian MR, Hayward CR and Burger HU: Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis. Anticancer Res 26: 479-484, 2006.
58. Langer CJ, Choy H, Glaspy JA and Colowick A: Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer 95: 613-623, 2002.
59. Hasegawa I and Tanaka K: Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. Gynecol Oncol 46: 65-68, 1992.
60. Beguin Y: Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 25: 27-34, 1998.
61. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T, Biron P and Blay JY: Risk model for severe anemia requiring red blood cell transformation after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 17: 2840-2846, 1999.
62. Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, and Freund M: Epoetin alfa corrects and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 21: 169-180, 2003.
63. Bokemeyer C, Oechsle K, Hartmann JT, Schoffski P, Schleucher N, Metzner B, Schleicher J and Kanz L: Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 87: 1066-1071, 2002.
64. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C and Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003.
65. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C and Engert A: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489-498, 2005.
66. Lichtin A: The ASH/ASCO clinical guidelines on the use of erythropoietin. Best Pract Res Clin Haematol 18: 433-438, 2005.
67. Sheffield RE, Sullivan SD, Saltiel E and Nishimura L: Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31: 15-22, 1997.
68. Dalton JD, Bailey NP, Barrett-Lee PJ and O'Brien MER: Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy. Proc Am Soc Clin Oncol 17: 418a, 1998.
69. Cremieux PY, Barrett B, Anderson K and Slavin MB: Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 18: 2755-2761, 2000.
70. Demetri GD: Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 84(Suppl 1): 31-37, 2001.
71. Morere JF: Role of epoetin in the management of anaemia in patients with lung cancer. Lung Cancer 46: 149-156, 2004.
72. Cheer SM, and Wagstaff AJ: Epoietin beta: a review of its clinical use in the treatment of anaemia in patients with cancer. Drugs 64: 323-346, 2004.
73. Engert A: Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol 2005, published electronically.
74. Adams JR, Elting LS, Lyman GH, George JN, Lembersky BC, Armitage JO, Demetri GD and Bennett CL: Use of erythropoietin in cancer patients: assessment of oncologist's practice patterns in the United States and other countries. Am J Med 116: 28-34, 2004.
75. Cleeland CS, Demetri GD, Glaspy J, Cella DF, Portenoy RK, Cremieux PY and Itri L: Identifying hemoglobin level for optimal quality of life: results of an incremental analysis. Proc Am Soc Clin Oncol 18: 574a, 1999.
76. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S and Vadhan-Raj S: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218-1234, 1997.
77. Gordon MS: Managing anemia in the cancer patient: old problems, future solutions. Oncologist 7: 331-341, 2002.
78. Santini D, Vincenzi B, La Cesa A, Virzi V, Navajas F, Malafarina V, Dicuonzo G, Cassandro R, Esposito V, Montesarchio V, Groeger AM and Tonini G: A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot trial. Anticancer Res 25: 669-674, 2005.
79. Mystakidou K, Kalaidopoulou O, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiatas ML and Vlahos L: Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment. Anticancer Res 25: 3495-3500.
80. Harrison LB, Shasha D, White C and Ramdeen B: Radiotherapy-associated anemia: the scope of the problem. Oncologist 5: 1-7, 2000.
81. Dempke W and Schmoll HJ: Mogliche neue Indikationen für die Therapie mit Erythropoietin. Med Klinik 96: 476-474, 2001.
82. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, and Gordon MS: Use of epoetin in patients with cancer: evidence-based clinical practise guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083-4107, 2002.
83. Patton J, Kuzur M, Liggett W, Miranda F, Varsos H and Porter L: Epoetin alfa 60000 U once weekly followed by 120000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 9: 90-96, 2005.
84. Egrie JC and Browne JK: Development and characterization of novel erythropiesis stimulating protein (NESP). Br J Cancer 84(Suppl 1): 3-10, 2001.
85. Vansteenkiste J and Wauters I: The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. Expert Opin Pharmacother 6: 429-440, 2005.
86. Osborne WR, Ramesh N, Lau S, Clowes MM, Dale DC and Clowes AW: Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA 92: 8055-8058, 1995.